TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Up 28.5% in May

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 2,300,000 shares, an increase of 28.5% from the April 30th total of 1,790,000 shares. Based on an average daily trading volume, of 557,200 shares, the days-to-cover ratio is presently 4.1 days. Currently, 5.3% of the company's shares are short sold.

Insider Transactions at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp purchased 1,200,000 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were acquired at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the purchase, the insider now owns 7,946,141 shares in the company, valued at $9,535,369.20. The trade was a 17.79% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.35% of the company's stock.

Institutional Trading of TScan Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Lynx1 Capital Management LP grew its holdings in TScan Therapeutics by 2.5% during the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock valued at $16,286,000 after purchasing an additional 132,747 shares during the period. BVF Inc. IL grew its holdings in shares of TScan Therapeutics by 63.6% in the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock valued at $6,747,000 after buying an additional 1,900,000 shares during the period. Checkpoint Capital L.P. raised its stake in TScan Therapeutics by 14.9% during the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock worth $2,784,000 after buying an additional 261,663 shares during the period. Aberdeen Group plc raised its stake in TScan Therapeutics by 0.9% during the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after buying an additional 7,744 shares during the period. Finally, abrdn plc lifted its holdings in TScan Therapeutics by 137.8% during the fourth quarter. abrdn plc now owns 883,704 shares of the company's stock worth $2,686,000 after acquiring an additional 512,049 shares in the last quarter. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Trading Up 7.1%

TCRX traded up $0.12 during trading on Friday, reaching $1.80. 213,072 shares of the company's stock were exchanged, compared to its average volume of 410,585. The company's fifty day moving average price is $1.40 and its 200-day moving average price is $2.24. The firm has a market capitalization of $101.86 million, a PE ratio of -1.70 and a beta of 0.98. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $9.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $2.17 million during the quarter, compared to analysts' expectations of $1.62 million. As a group, equities analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wedbush reaffirmed an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a report on Tuesday, May 6th. HC Wainwright dropped their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley reissued an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Friday, March 14th. Needham & Company LLC reissued a "buy" rating and set a $9.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Finally, Barclays cut their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $7.80.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.